CALGB(Alliance)100104研究更新分析:多发性骨髓瘤单次自体干细胞移植后来那度胺与安慰剂维持治疗的比较——随机双盲3期试验
CALGB(Alliance)100104研究更新分析中位随访91个月,来那度胺组231例、安慰剂组229例,来那度胺组中位至进展时间57.3个月,安慰剂组28.9个月,HR 0.57(95%CI 0.46-0.71,p<0.0001);来那度胺组3-4级中性粒细胞减少和血小板减少及第二原发肿瘤更多,但至进展时间显著改善,作者认为可考虑作为标准治疗。
要点
- 中位随访91个月,来那度胺组中位至进展时间57.3个月,安慰剂组28.9个月,HR 0.57(95%CI 0.46-0.71,p<0.0001)
- 来那度胺组3-4级中性粒细胞减少116例(50%),安慰剂组41例(18%);血小板减少34例(15%)vs 12例(5%)
- 来那度胺组血液系统第二原发肿瘤18例(8%)、实体瘤14例(6%),安慰剂组分别为3例(1%)和9例(4%)
核心结论
- 尽管血液学不良事件和第二原发肿瘤增加,自体干细胞移植后来那度胺维持治疗仍显著改善至进展时间,作者认为可考虑作为标准治疗。
研究设计与样本
- 随机双盲安慰剂对照3期试验,纳入需治疗的症状性多发性骨髓瘤、诱导方案不超过2种、自体干细胞移植后100天内达疾病稳定或更好者。
- 2005年4月14日至2009年7月2日共随机分配460例,来那度胺组231例,安慰剂组229例;按β2微球蛋白≤2.5 mg/L vs >2.5 mg/L、诱导期间是否用过沙利度胺、是否用来那度胺分层。
- 来那度胺起始剂量每日2粒(10 mg),3个月后升至每日3粒(15 mg);主要终点为至进展时间,意向性分析;中位随访91个月(IQR 83.6-103.1)。
主要发现
- 来那度胺组中位至进展时间57.3个月(95%CI 44.2-73.3),安慰剂组28.9个月(95%CI 23.0-36.3),HR 0.57(95%CI 0.46-0.71,p<0.0001)。
- 3-4级中性粒细胞减少来那度胺组116例(50%)vs 安慰剂组41例(18%);血小板减少34例(15%)vs 12例(5%)。
- 随机化后疾病进展前诊断第二原发肿瘤:来那度胺组血液系统18例(8%)、实体瘤14例(6%);安慰剂组血液系统3例(1%)、实体瘤9例(4%),其中安慰剂组交叉亚组有3例血液系统、5例实体瘤。
- 中位随访18个月时揭盲,安慰剂组无进展的128例中86例(67%) crossover至来那度胺组。
临床怎么用
- 作者认为自体干细胞移植后来那度胺维持治疗可考虑作为标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. Here we report an updated intention-to-treat analysis of CALGB (Alliance) 100104 at a median follow-up of 91 months. METHODS: Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they had symptomatic disease requiring treatment; had received, at most, two induction regimens; and had achieved stable disease or better in the first 100 days after ASCT. We randomly assigned patients to either lenalidomide or placebo groups using permuted block randomisation, with a fixed block size of six. Randomisation was stratified by three factors: normal or elevated β2 microglobulin concentration at registration (≤2·5 mg/L vs >2·5 mg/L), previous use or non-use of thalidomide during induction therapy, and previous use or non-use of lenalidomide during induction therapy. The starting dose was two capsules (10 mg) per day, escalated to three capsules (15 mg) per day after 3 months. The primary endpoint was time to progression (time of progressive disease or death from any cause), with intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00114101. New patients are no longer being recruited, but some patients remain on treatment and in follow-up. FINDINGS: Between April 14, 2005, and July 2, 2009, 460 patients were randomly assigned to receive either lenalidomide (n=231) or placebo (n=229). After three interim analyses, the study was unblinded at a median follow-up of 18 months, at which point 86 (67%) of 128 patients without progressive disease in the placebo group chose to cross over to the lenalidomide group. The median follow-up for the updated survival analysis, as of Oct 19, 2016, was 91 months (IQR 83·6-103·1). The median time to progression was 57·3 months (95% CI 44·2-73·3) for the lenalidomide group and 28·9 months (23·0-36·3) for the placebo group (hazard ratio 0·57, 95% CI 0·46-0·71; p<0·0001). The most common grade 3-4 adverse events were neutropenia (116 [50%] patients in the lenalidomide group and 41 [18%] patients in the placebo group) and thrombocytopenia (34 [15%] patients in the lenalidomide group and 12 [5%] patients in the placebo group). 18 (8%) haematological and 14 (6%) solid tumour second primary malignancies were diagnosed after randomisation and before disease progression in the lenalidomide group, compared with three (1%) haematological and nine (4%) solid tumour second primary malignancies in the placebo group. Three haematological and five solid tumour second primary malignancies in the placebo group were in the crossover subgroup. INTERPRETATION: Despite an increase in haematological adverse events and second primary malignancies, lenalidomide maintenance therapy after ASCT significantly improved time to progression and could be considered a standard of care. FUNDING: The National Cancer Institute.
引用
- Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017. PMID: 28826616. doi:10.1016/S2352-3026(17)30140-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。